The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 28, 2021

Filed:

Nov. 21, 2017
Applicant:

Case Western Reserve University, Cleveland, OH (US);

Inventor:

Michael A. Weiss, Moreland Hills, OH (US);

Assignee:

Case Western Reserve University, Cleveland, OH (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/28 (2006.01); C07K 14/62 (2006.01); A61P 3/10 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/62 (2013.01); A61P 3/10 (2018.01); A61K 38/00 (2013.01);
Abstract

A two-chain insulin analogue contains a modified A-chain polypeptide and a modified B-chain polypeptide. The A-chain polypeptide comprises one or more of: a His or Glu substitution at position A8, a Glu substitution at position A14; and a Gln or Arg substitution at positon A17. The B-chain polypeptide comprises one or more of: a deletion of the amino acids at position B1, B1-B2, B1-B3, B30 or a combination thereof; an Ala or Glu substitution at position B2; a Glu substitution at position B3. The analogue exhibits thermodynamic stability in a zinc-free solution, decreased self-association, maintains biological potency, and no increased mitogenicity. The analogue exhibits resistance to chemical degradation and physical degradation. A method of treating a patient with diabetes mellitus or obesity comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient.


Find Patent Forward Citations

Loading…